Risk factors
Equillium (EQ) risk factors
Item 1A of every Equillium, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors91 risks23 new21 dropped30 reworded
Pipeline shifted from itolizumab to new product candidates EQ504 and EQ302, requiring substantial additional capital.
Filed Mar 25, 2026 - FY2024 10-K risk factors89 risks
Clinical-stage biotech focused on itolizumab and immune-modifying therapies, facing substantial ongoing losses and capital raising needs.
Filed Mar 27, 2025